JPRN-UMIN000009380招募中2 期
Adjuvant treatment of novel multiple cancer vaccine restricted with HLA-A24 for patients with completely resected non-small cell lung cancer. randomized phase II trial - Adjuvant treatment of multiple cancer vaccine for patients with completely resected non-small cell lung cancer. randomized phase II trial
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. With uncontrollable ischemic heart disease and/or arhythmia 2. With acute myocardial infarction 6 months before treatment 3. Lactating, pregnant or possibly pregnant women, or those willing to become pregnant 4. With double cancer, multiple cancer 5. With active inflammatory disease 6. With steroidal or immunosuppressive agent dependency 7. Physician concludes that the patient's participation in this trial is inappropriate
研究者
相似试验
已完成
1 期
Tumor specific vaccination therapy for advanced/recurrent ovarian cancer using HLA-A*0201 restricted Specific Epitope Peptides Cocktail derived from Tumor genom/Tumor related Angiogenetic factors genomadvanced/recurrent ovarian cancer with the conditions of unremoval by surgery, or refractory, chemo-resistant disease.JPRN-UMIN000003860Iwate Medical University School of Medicine Department of Obstetrics and Gynecology30
已完成
1 期
Tumor specific vaccination therapy for advanced/recurrent cervical cancer using HLA-A*0201 restricted Specific Epitope Peptides Cocktail derived from Tumor genom/Tumor related Angiogenetic factors genomadvanced/recurrent cervical cancer with the conditions of unremoval by surgery, or refractory, chemo-resistant disease.JPRN-UMIN000003903Iwate Medical University School of Medicine department of Obastetrics and Gynecology30
已完成
1 期
Tumor specific vaccination therapy for advanced/recurrent cervical cancer using HLA-A*2402 restricted Specific Epitope Peptides Cocktail derived from Tumor genom/Tumor related Angiogenetic factors genomJPRN-UMIN000003902Iwate Medical University School of Medicine department of Obstetrics and Gynecology30
已完成
1 期
Tumor specific vaccination therapy for advanced/recurrent ovarian cancer using HLA-A*2402 restricted Specific Epitope Peptides Cocktail derived from Tumor genom/Tumor related Angiogenetic factors genomadvanced/recurrent ovarian cancer with the conditions of unremoval by surgery, or refractory, chemo-resistant disease.JPRN-UMIN000003862Iwate Medical University School of Medicine department of obstetrics and gynecology30
已完成
不适用
Cancer vaccine in combination with down-modulation of regulatory T cells for patients with incurable cancerJPRN-UMIN000003613Department of Clinical Oncology, Kawasaki Medical School80